Founded in 2021 and headquartered in Zug, Switzerland, MoonLake is positioned as a pure-play developer of sonelokimab for immunologic dermatologic and rheumatologic diseases. The company secured up to $500 million in non-dilutive financing from Hercules Capital, extending cash runway into 2028. Strong analyst support and de-risked regulatory pathway support growth potential through 2026-2027 product launch.
Cyborg Score Rationale
Phase 3 VELA program showed statistically significant improvements across primary endpoints with favorable safety profile and no new safety signals. Strong balance sheet with $425.1 million cash and debt capacity runway into 2028 supports clinical execution. However, VELA-2 missed primary statistical significance (p=0.053) due to higher placebo response, introducing some regulatory uncertainty.
Top Insights
FDA granted Fast Track designation to sonelokimab for moderate-to-severe palmoplantar pustulosis based on positive Phase 2 LEDA results.
Planned BLA submission for hidradenitis suppurativa in H2 2026 with phase 2 S-OLARIS axSpA data and 2026 catalysts.
Analyst consensus is "Buy" with 12-month stock price target of $36.33, representing 143.83% upside from latest price.
Anticipates product launch in 2027 pending regulatory approvals.
Named Competitors
Risankizumab — IL-23 inhibitor for psoriasis and inflammatory diseases
IL-17 inhibitors (pipeline) — Competing monoclonal antibodies in dermatology/rheumatology space